MarketWatch  Nov 4  Comment 
Shares of PerkinElmer Inc. fell 5.6% in early trades Friday after the scientific instruments maker reported lower-than-expected revenues in its quarterly earnings release late Thursday. Revenue rose 8% to $453.7 million, as analysts polled by...
Investment Underground » Page not found  Sep 15  Comment 
The market eagerly anticipated President Obama’s job speech on Thursday, and popular ETFs like DIA, QQQ, and SPY finished down for the day.
Market Intelligence Center  Sep 14  Comment 
Caliper Life Sciences (NASDAQ: CALP) hit a new 52-Week high of $10.55 Tuesday. The stock closed up $.05 (0.48%) to $10.54 on 3,087,258 shares traded. Yesterday's high is up $7.21 from a 52-Week Low of $3.33. Caliper Life Sciences stock has been...
Benzinga  Sep 12  Comment 
Jefferies & Company has downgraded Caliper Life Sciences (NASDAQ: CALP) from Buy to Hold and has raised the price target from $10 to $10.50. nop (c) 2011 Benzinga.com. All rights...
StreetInsider.com  Sep 8  Comment 
Caliper Life Sciences, Inc. (Nasdaq: CALP) 41.0% HIGHER; PerkinElmer, Inc. (NYSE: PKI) has signed a definitive agreement to acquire Caliper for $10.50 per share, for a total net purchase price of approximately $600 million in cash. Coldwater...
Forbes  Sep 8  Comment 
Scientific instruments maker PerkinElmer (PKI) said today it has agreed to acquire Caliper Life Sciences (CALP) for $10.50 per share in cash. The deal for the imaging and detection solutions developer for the life sciences, diagnostics and...
MarketWatch  Sep 8  Comment 
MarketWatch’s daily rundown of shares making sizable moves in the U.S. stock market.
Benzinga  Sep 8  Comment 
Caliper Life Sciences Inc (NASDAQ: CALP) added 39.78% to $10.33 in the pre-market session. PerkinElmer Inc (NYSE: PKI) announced its plans to acquire Caliper Life Sciences for $10.50 per share. Smithfield Foods Inc (NYSE: SFD) surged 3.75% to...
MarketWatch  Sep 8  Comment 
Caliper Life Sciences Inc., the Hopkinton, Mass., provider of imaging and detection solutions for life-sciences, diagnostics and environmental applications, agreed to be acquired by PerkinElmer Inc. for $10.50 a share, or $600 million....
StreetInsider.com  Aug 31  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Caliper+Life+Sciences+%28CALP%29+Announces+Availability+of+Spectrum+CT+/6753428.html for the full story.


Related Articles


Based in Hopkinton, MA, Caliper Life Sciences, Inc. (CALP) develops and commercializes life science instruments and related consumables and services for use in drug discovery and development and other life sciences research. Caliper makes specialized LabChips (roughly one-inch in diameter) that miniaturize, integrate, and automate laboratory functions, with the intention of enhancing the capabilities, and reducing the size of laboratories. Microfluidic chips, experiment-specific reagents, and related software are the main constituents of these specialized systems. The chips consist of a network of miniaturized, microfabricated channels through which chemicals and other fluids can be transported. After introducing reagents (chemical agents, dyes, or other materials required for biological experiments) automatically or by the user depending on the chip format, the instrument and specialized software (for scheduling, integration, and data management) after placement of the chip move the fluids in the network with pressure or electricity. Additionally, Caliper's high and ultra-high throughput screening systems, liquid handlers, advanced robotics (for automation), storage devices, and workstations (for dissolution, extraction, and evaporation) offer complete solutions to the pharmaceutical, biotechnology, chemical, agriculture, and food industries. The company s systems improve research efficiency by providing more accurate data at lower costs and higher speeds. The acquisition of NovaScreen in October 2005 expanded Caliper s service offerings. The acquisition of Xenogen in August 2006 expanded the company into the molecular imaging market. With Xenogen s imaging technologies, Caliper is able to provide an integrated package of products and services for both in vitro and in vivo research in drug discovery. In 2006, product revenue, service revenue (product support, validation services, drug discovery & development services, screening & profiling services, assay development services, & contract research & transgenic animal services), and license fees and contract revenue (from collaborations) contributed 64%, 22%, and 14%, respectively, to total revenue.


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki